

Last edit: June 2, 2026

**Wednesday, July 15****Continental Breakfast****7:15 AM****8:15 AM****Retina Around the Globe (No CME, livestream, or recording)**

**Team 1** Moderators: RV Paul Chan, MD, MSc, MBA and Mrinali Gupta, MD, FASRS Presenters: Gustavo Huning, MD, MBA, FASRS; Ajay Kuriyan, MD, MS; Ahmed Mansour, MBBCH, MSc, MD, PhD; Ayumi Ouchi, MD, MD, PhD; Cynthia Qian, MD; Sara Touhami, MD, PhD, FEBO, HDR

**8:00 AM****11:00 AM**

**Team 2** Moderators: Rajeev Muni, MD, MSc, FRCS(C), FASRS and Nimesh Patel, MD, FASRS Presenters: Lalit Agarwal, MD; Kunihiro Akiyama, MD, PhD; Thibault Chapron, MD, PhD; Luis Escaf, MD; Natasha Ferreira Santos da Cruz, MD; Jessica Xiong, BMed/MD, Mmed

**Team 3** Moderators: Jorge Fortun, MD and Aleksandra Rachitskaya, MD, FASRS Presenters: Fares Antaki, MDCM, FRCSC; Andres Aqueveque, MD, FEBO, PhD; Bruna Gil Ferriera, MD; Yassine Malek, MD; Joaquin Sosa, MD; Marcelo Ventura, MD

**Circus of Complications (No CME, livestream, or recording)**

Moderators: Mohsin Ali, MD; Brian Do, MD, FASRS; Lisa Olmos de Koo, MD, MBA; Priya Vakharia, MD, FASRS

**11:00 AM****12:15 PM**

Presenters: Edward Korot, MD; Gregory Lee, MD; Tamara Lenis, MD, PhD; Matthew Trese, DO, MA; Malek Yassine, MD; Sarwar Zahid, MD, FASRS

General Lunch + International Lunch; Exhibits Open

**12:15 PM****1:30 PM****Medical Case Conference**

Moderators: Ines Lains, MD, PhD; Anat Loewenstein, MD

**1:30 PM****3:00 PM**

	<p><u>Presenters:</u> Mohamed Al Bahiti, MBBS, FRCSC; Parnian Arjmand, MD, MSc, FRCSC, DABO; Poornachandra B, MS, FVRS; Kevin Blinder, MD, FASRS; Victor Chen, MD; Talisa de Carlo Forest, MD; Hector Ibanez, MD, FACS, FASRS, FABO, FAAO; Matias Igllicki, MD; Ravi Keshavamurthy, MBBS, MD; Ricardo Leal Rodriguez, MD; Sun Young (Sunny) Lee, MD, PhD, FASRS, FARVO; Yasha Modi, MD; Nader Moinfar, MD, MPH, FACS, FASRS; Samir Patel, MD; Sriharanathan Poopalaratnam, MD, FRCSC; Emil Anthony Say, MD; Kotaro Tsuboi, MD; Eduardo Uchiyama, MD, FACS</p>		
Break		3:00 PM	3:40 PM
<b>Surgical Case Conference</b>	<p><u>Moderators:</u> Carl Awh, MD, FASRS; Caroline Awh, MD</p>	3:40 PM	5:10 PM
	<p><u>Presenters:</u> Luis Acaba-Berrocal, MD; Sulaiman Al Sulaiman, MD; Alay Banker, MD; Mauricio Bayram-Suverza, MD; Yodpong Chantarasorn, MD; Jordan Deaner, MD; Charles DeBoer, MD, PhD; Masaki Fukushima, MD, PhD; Raymond Iezzi, MD, MS; Srinivas Joshi, MD, FASRS; Boonkit Purt, MD, FACS; Padmaja Rani, M.S, FICO, FRCSC; Mary-Grace Reeves, MD, MBA; Geovanni Rios, PhD, MD; Pukhraj Rishi, MBBS, MS, DO, FRCS, FRCSEd, FASRS, FACS; Ahmed Sallam, MD PhD FRCOphth; Homayoun Tabandeh, MD, FASRS; Christina Weng, MD, MBA, FASRS</p>		
Opening Reception: Grand Quai Pavilion		6:30 PM	
<b>Thursday, July 16</b>			
Experience Center (Fellows & Residents)		6:30 AM	7:30 AM
Continental Breakfast		7:15 AM	8:15 AM
Opening Comments		8:00 AM	8:05 AM
Welcome to Montreal		8:05 AM	8:10 AM
AMD - Neovascular Panel. <i>Beyond Anti-VEGF: Emerging Durable Therapies in Neovascular AMD</i>		8:10 AM	8:45 AM

One-year, First-in-Human, Safety and Efficacy Data for Subretinal NG101 - a Novel Low-dose AAV Gene Therapy for Wet AMD: A Phase 1/2a Clinical Trial	<b>Peter Kertes, MD, FRCS(C)</b>		
Ixoberogene soroparvovec (Ixo-vec) intravitreal gene therapy for neovascular age-related macular degeneration (nAMD): LUNA trial 2-year results	<b>Shawn Kavoussi, MD</b>		
Ixoberogene soroparvovec intravitreal gene therapy for neovascular age-related macular degeneration: Long-term results from the OPTIC trial	<b>Szilard Kiss, MD, FASRS</b>		
Intravitreal Axitinib Hydrogel (OTX-TKI) in Neovascular Age-Related Macular Degeneration: Efficacy and Safety Results from the Phase 3 SOL-1 Trial	<b>Dilsher Dhoot, MD</b>		
Results of a Randomized, Proof-of-Concept Clinical Trial Comparing OLN324 with Faricimab in Patients with Neovascular Age-Related Macular Degeneration	<b>David Eichenbaum, MD, FASRS</b>		
Efficacy and safety of aflibercept 8 mg in previously treated patients with nAMD or DME: 24-week results from the phase 3b ELARA trial	<b>Eric Schneider, MD</b>		
Discussion			
<i>Transition</i>		8:45 AM	8:47 AM
<b>Real-World Symposium 1. Real-World nAMD: Utilization, Outcomes, and Long-Term Anti-VEGF Data</b>		<b>8:47 AM</b>	<b>9:11 AM</b>
Utilization and Trends in Anti-Angiogenic and Anti-Complement Therapeutics from 2023-2025	<b>Anton Kolomeyer, MD, PhD</b>	8:47 AM	8:50 AM
Real-World Anti-VEGF Treatment Utilization and Vision Outcomes in Neovascular Age-Related Macular Degeneration: Analysis of the Vestrum Database	<b>Andrew Moshfeghi, MD, MBA, FASRS</b>	8:50 AM	8:53 AM
Real-World Efficacy and Safety of Faricimab in Neovascular Age-Related Macular Degeneration: First Time 4.5 Year Results of the TRUCKEE Study	<b>Carl Danzig, MD</b>	8:53 AM	8:56 AM
Long-Term Effectiveness and Safety of Faricimab in Eyes With nAMD: 2-Year Results From the UK FARWIDE Study	<b>Ian Pearce, MB ChB BSc FRCOPHTH</b>	8:56 AM	8:59 AM
Discussion		8:59 AM	9:11 AM
<i>Transition</i>		9:11 AM	9:13 AM

<b>Surgical Techniques and Maneuvers Panel. <i>Mastering Scleral Fixation: Techniques, Pearls, and Pitfalls</i></b>		<b>9:13 AM</b>	<b>9:43 AM</b>
A NOVEL MODIFIED FLAPLESS SURGICAL TECHNIQUE FOR SUTURELESS SCLERAL FIXATION OF FIL SSF INTRAOCULAR LENS: A PROSPECTIVE STUDY	<b>Danilo Iannetta, MD, PhD</b>		
Closed-Globe Internal Refixation of Dislocated PMMA Scleral-Fixated IOLs Using a Modified Double-Flanged Polypropylene Technique: A prospective interventional study	<b>Srinivas Joshi, MD, FASRS</b>		
Sutureless Flanged Versus Gore-Tex for Secondary IOL implantation: A Comparative Analysis of Surgical Philosophy, Biomechanics, and Clinical Outcomes	<b>Matias Iglicki, MD</b>		
Lens Tilt and Dislocation After Modified Yamane Fixation: Association With Prophylactic Laser to the Optic-Haptic Junction	<b>Harris Sultan, MS, MD</b>		
Platform Matters? - Comparative Effectiveness of Five Vitrectomy Systems in 1,082 Primary Vitreoretinal Surgeries	<b>Obuli Nandhakumar, MD, MRCS, AMPH</b>		
Discussion			
Break		<b>9:43 AM</b>	<b>10:23 AM</b>
<b>AMD - Neovascular Symposium 1. <i>Rethinking nAMD Care: Home OCT, Treatment Burden, and Real-World Barriers</i></b>		<b>10:23 AM</b>	<b>10:47 AM</b>
Longitudinal Performance of a Trend Analysis Algorithm for Home OCT Monitoring in Neovascular Age-related Macular Degeneration (NVAMD)	<b>Anat Loewenstein, MD</b>	10:23 AM	10:26 AM
Macular Ganglion Cell Layer Stability After Repeated Anti-VEGF Therapy in Eyes With and Without Primary Open-Angle Glaucoma	<b>Marco Rovati</b>	10:26 AM	10:29 AM
Economic Evaluation of Home OCT: Determinants of Cost-Sparing Potential, Patient Selection, and Clinical Burden	<b>Sean Berkowitz, MD, MBA</b>	10:29 AM	10:32 AM
Impact of Treatment Delays Due to Prior Authorization on Short-term Visual Acuity in Neovascular Age-Related Macular Degeneration	<b>Mingyi Huang, MD</b>	10:32 AM	10:35 AM
Discussion		10:35 AM	10:47 AM
Transition		10:47 AM	10:49 AM

<b>Imaging - Digital - Angiography Symposium. <i>Innovations in Retinal Angiography and Functional Imaging</i></b>		<b>10:49 AM</b>	<b>11:08 AM</b>
Optoretinography (ORG) for Macular Dysfunction	<b>Kareem Moussa, MD</b>	10:49 AM	10:52 AM
Diagnostic accuracy and sensitivity of ultra-widefield steering-based imaging to detect peripheral retinal breaks	<b>Kevin Blinder, MD, FASRS</b>	10:52 AM	10:55 AM
Synergistic Visions - OCT Angiography and Dynamic Adaptive Optics Angiography for Clinical Assessment of Retinal Microvasculopathy	<b>Richard Rosen, MD, DSc(Hon), FACS, FASRS, FARVO</b>	10:55 AM	10:58 AM
Discussion		10:58 AM	11:08 AM
<i>Transition</i>		11:08 AM	11:10 AM
<b>Complications of Anterior Segment Surgery Panel. <i>When Things Go Wrong: Complications and Decision-Making in Secondary IOL Surgery</i></b>		<b>11:10 AM</b>	<b>11:35 AM</b>
Comparative Outcomes of Secondary Intraocular Lens Fixation Techniques: Retrospective Analysis of 935 case	<b>Bryon McKay, MD, PhD, FRCSC, DRCPSC - Retina</b>		
Is 20/20 Vision Good Enough? Outcomes of Complete Pars Plana Vitrectomy During IOL Exchange for Lens Opacification in Patients with Preserved Visual Acuity	<b>Ofri Vorobichik Berar, MD, MHA</b>		
Scleral-Suture Secondary Intraocular Lens Implantation Using a Modified Scleral Mesh (Hash-Tag) Technique: Case Series	<b>Carmen Negrin-Martin, MD</b>		
Structural and Functional Outcomes and Recovery Spectrum in Intracameral Cefuroxime Ocular Toxic Syndrome (ICOTS) in Eyes with Disrupted Intraocular Barrier	<b>Andrea Cusumano, MD</b>		
Discussion			
<i>Transition</i>		<b>11:35 AM</b>	<b>11:37 AM</b>
<b>Awards Ceremony</b>		<b>11:37 AM</b>	<b>12:14 PM</b>
Pyron Award Introduction	<b>Geoffrey G. Emerson, MD, PhD, FASRS</b>	11:37 AM	11:39 AM
Pyron Award: Deep Learning Algorithm to Quantify Gyrate Atrophy Lesions	<b>Glenn Jaffe, MD</b>	11:39 AM	11:44 AM
Founders Award Introduction	<b>Audina Berrocal, MD, FASRS</b>	11:44 AM	11:46 AM
Founders Award: From Illumination to Visualization: A Laser Light Source and an Illuminated Vitreous Cutter	<b>Carl Awh, MD, FASRS</b>	11:46 AM	11:51 AM
Young Investigator Award Introduction	<b>J. Michael Jumper, MD, FASRS</b>	11:51 AM	11:53 AM

Young Investigator Award: The Retina Mosaic	<b>Yoshihiro Yonekawa, MD, FASRS</b>	11:53 AM	11:58 AM
Packo Award Presentation to Joel Pearlman, MD, PhD	<b>Geoffrey G. Emerson, MD, PhD, FASRS</b>	11:58 AM	12:00 PM
Crystle Apple Award Presentation to Herbert Culver Boldt, MD	<b>Brian Do, MD, FASRS &amp; Priya Vakharia, MD, FASRS</b>	12:00 PM	12:02 PM
WinR Champion Award		12:02 PM	12:04 PM
Tribute Giving	<b>J. Michael Jumper, MD, FASRS</b>	12:04 PM	12:06 PM
2026 M. Gilbert Grand ASRS Vitreoretinal Fellowship Award	<b>J. Michael Jumper, MD, FASRS</b>	12:06 PM	12:08 PM
Retina Image Bank Image of the Year	<b>Ajay Kuriyan, MD, MS &amp; Katherine Talcott, MD</b>	12:08 PM	12:09 PM
Retina Atlas Chapter of the Year	<b>Ajay Kuriyan, MD, MS &amp; Katherine Talcott, MD</b>	12:09 PM	12:10 PM
Retina Hall of Fame Lifetime Achievement Award	<b>John Thompson, MD</b>	12:10 PM	12:12 PM
Transition		12:12 PM	12:14 PM
General Lunch + ECS Lunch		<b>12:14 PM</b>	<b>1:29 PM</b>
<b>Business Meeting</b>		<b>1:29 PM</b>	<b>1:44 PM</b>
<i>Transition</i>		1:44 PM	1:46 PM
<b>AMD - Non-neovascular Symposium 1. <i>Beyond Atrophy: Restoring Vision and Redefining Care in Geographic Atrophy</i></b>		<b>1:46 PM</b>	<b>2:10 PM</b>
Vision Improvement with Sonporetigene Isteparvovec Optogenetic Therapy in Macular Degeneration: First Direct-to-Phase 2 Randomized, Controlled Trial	<b>Jordi Mones, MD PhD</b>	1:46 PM	1:49 PM
From Optical Modelling to First-in-Human Add-On Implantation of the SING IMT™: Translational Feasibility of Dual-Lens Intraocular Systems for Late-Stage AMD	<b>Stanislao Rizzo, MD</b>	1:49 PM	1:52 PM
Liquid Biopsy Proteomics: Deciphering the Molecular Mechanisms Behind Increased Neovascular AMD Risk After Anti-complement Therapy in Geographic Atrophy	<b>Tsai-Chu Yeh, MD, MTM</b>	1:52 PM	1:55 PM
Artificial Intelligence in GA: Learnings from the Pegcetacoplan Clinical Program	<b>Paul Hahn, MD, PhD, FASRS</b>	1:55 PM	1:58 PM
Discussion		1:58 PM	2:10 PM
<i>Transition</i>		2:10 PM	2:12 PM
<b>Diabetic Retinopathy Panel 1. <i>Advancing Durability in Diabetic Retinopathy: New Therapies and Long-Term Data</i></b>		<b>2:12 PM</b>	<b>2:42 PM</b>
Long-Term Effectiveness and Safety of Faricimab in Eyes With DME: 2-Year Results From the UK FARWIDE Study	<b>Sobha Sivaprasad, FRCOphth</b>		

Intravitreal Tarcocimab Tedromer for Diabetic Retinopathy: First-time, Primary Endpoint Results from the Phase 3 GLOW2 Trial	<b>Charles Wykoff, MD, PhD, FASRS</b>		
Pagoda Trial Results Through Year 4: Port Delivery Platform With Ranibizumab for the Treatment of Diabetic Macular Edema	<b>Luke Lindsell, OD, MD</b>		
Results of a Randomized, Proof-of-Concept Clinical Trial Comparing OLN324 with Faricimab in Patients with Diabetic Macular Edema	<b>Veeral Sheth, MD, MBA, FASRS, FACS</b>		
Intravitreal Tarcocimab Tedromer for Diabetic Retinopathy: First-time Cross-trial Evaluation of the GLOW and GLOW2 Phase 3 Trials	<b>David Brown, MD</b>		
Discussion			
Break		<b>2:42 PM</b>	<b>3:22 PM</b>
<b>Real-World Symposium 2. Managing Macular Edema in the Real World: What the Data Shows</b>		<b>3:22 PM</b>	<b>3:46 PM</b>
Two-Year Real-World Outcomes of Faricimab for Diabetic Macular Edema: Updated Results from the US FARETINA-DME Expanded 2 year cohort in the IRIS® Registry	<b>Murtaza Adam, MD</b>	3:22 PM	3:25 PM
Real-World Use of Aflibercept 8 mg in Eyes with Diabetic Macular Edema (DME): Analysis of the IRIS® Registry (ILLUMIN-8 6-mo)	<b>Michael Klufas, MD</b>	3:25 PM	3:28 PM
Durability and safety of suprachoroidal triamcinolone acetonide in eyes with chronic cystoid macular edema in real-world clinical practice	<b>Sunir Garg, MD, FACS, FASRS</b>	3:28 PM	3:31 PM
Real-World Clinical Outcomes in Patients With Retinal Vein Occlusion With Macular Edema Treated With Faricimab in the Academy IRIS® Registry	<b>Rishi Singh, MD</b>	3:31 PM	3:34 PM
Discussion		3:34 PM	3:46 PM
<i>Transition</i>		3:46 PM	3:48 PM
<b>Macular Holes &amp; Macular Pucker Panel 1. Beyond the ILM Flap: Advanced Techniques for Complex Macular Holes</b>		<b>3:48 PM</b>	<b>4:13 PM</b>
Impact of Phacoemulsification on Vitreomacular Traction Release and Complications	<b>Ananth Sastry, MD</b>		

Beyond the Inverted Flap: Clinical utility of a non-inverted ILM free flap and SPOT technique for primary and refractory Macular Holes	<b>Peiquan Zhao, MD</b>		
Predictors of Anatomic and Functional Success with Amniotic Membrane Grafting for Complex Macular Holes	<b>Scott Walter, MD, MSc, FASRS</b>		
Distal ILM Flap for Extra-large, XX-large, and Giant Macular Holes	<b>Homayoun Tabandeh, MD, FASRS</b>		
Discussion			
<i>Transition</i>		4:13 PM	4:15 PM
<b>Technology: Updates in Artificial Intelligence (AI), Augmented Reality, and Robotics. AI in Retina: From Prediction to Clinical and Surgical Decision-Making</b>		<b>4:15 PM</b>	<b>4:39 PM</b>
Prospective Evaluation of AI-Assisted Screening for Clinical Trials in a Real World Setting	<b>Louis Cai, MD</b>	4:15 PM	4:18 PM
Predicting Anti-VEGF Treatment Response in Diabetic Macular Edema Using Automated OCT Biomarkers	<b>Peter Clark, MD</b>	4:18 PM	4:21 PM
OCT-F: An AI-Enabled Tool to Determine Retinal Function from OCT	<b>Srinivas Sadda, MD</b>	4:21 PM	4:24 PM
bu	<b>Michael Singer, MD</b>	4:24 PM	4:27 PM
Discussion		4:27 PM	4:39 PM
<i>Transition</i>		4:39 PM	4:41 PM
<b>Macular Holes &amp; Macular Pucker Symposium. Beyond the ILM Flap: Advanced Techniques for Complex Macular Holes</b>		<b>4:41 PM</b>	<b>5:05 PM</b>
Redefining Anatomic Success After Vitrectomy for Lamellar Macular Hole (LMH): Clinical Impact of Persistent or Recurrent LMH and Progression to Full-Thickness Macular Hole	<b>Masaki Fukushima, MD</b>	4:41 PM	4:44 PM
Spontaneous Progression from Lamellar Macular Hole to Full-Thickness Macular Hole: Timing, Characteristics, and Surgical Outcomes	<b>Kotaro Tsuboi, MD</b>	4:44 PM	4:47 PM
Postoperative stages of macular hole recovery through transfluid optical coherence tomography: a comparison between minimal gas vitrectomy and fluid-gas exchange	<b>Yodpong Chantarasorn, MD</b>	4:47 PM	4:50 PM

Early Epiretinal Membrane Surgery Is Associated With Improved Visual Outcomes After Macula-On Retinal Detachment: A Large Database Study	<b>Paul de Bustros, MD, MS</b>	4:50 PM	4:53 PM
Discussion		4:53 PM	5:05 PM
Transition		5:05 PM	5:10 PM
<b>Scientific Poster Q&amp;A and Exhibit Hall Reception</b>		<b>5:10 PM</b>	<b>6:10 PM</b>
<b>Friday, July 17</b>			
<b>Experience Center (Fellows &amp; Residents)</b>		<b>6:30 AM</b>	<b>7:30 AM</b>
<b>Continental Breakfast</b>		<b>7:15 AM</b>	<b>8:15 AM</b>
<b>AMD - Neovascular Symposium 2. <i>Innovations in nAMD: New Targets, New Therapies, Early Results</i></b>		<b>8:00 AM</b>	<b>8:19 AM</b>
First-in-Human Evaluation of TH103, a Novel Dual-Targeting VEGF/HSPG Biologic: Phase 1 Single Ascending Dose Study in Treatment-Naïve Neovascular AMD	<b>Joel Pearlman, MD, PhD</b>	8:00 AM	8:03 AM
Efficacy and Safety of a Novel Topical Peptide (CG-P5) for the Treatment of Neovascular Age-Related Macular Degeneration: Phase 1 Results	<b>David Almeida, MD, MBA, PhD, DABO, FRCSC, FASRS</b>	8:03 AM	8:06 AM
Randomized, Controlled, Double-Masked Study to Evaluate the Antimicrobial Efficacy of IRX-101: STERILE Trial Results	<b>STEPHEN SMITH, MD</b>	8:06 AM	8:09 AM
Discussion		8:09 AM	8:19 AM
Transition		8:19 AM	8:21 AM
<b>AMD - Non-neovascular Symposium 2. <i>Emerging Therapies in Geographic Atrophy: Gene Therapy, RNA, and Novel Pathways</i></b>		<b>8:21 AM</b>	<b>8:45 AM</b>
Subretinal Novel Modifier Gene Therapy (OCU410) for Geographic Atrophy: First-Time 1 year Results from the Phase 2 ArMaDa Trial.	<b>Arshad Khanani, MD, MA, FASRS</b>	8:21 AM	8:24 AM
Phase 1/2 Evaluation of OCU410 Novel Modifier Gene Therapy for Geographic Atrophy and Stargardt Disease: Quantitative FAF and SD-OCT Lesion Analysis and Safety Outcomes	<b>Jay Chhablani</b>	8:24 AM	8:27 AM
Phase 1 results of APL-3007: A novel systemic C3 siRNA for geographic atrophy secondary to AMD	<b>Mathew MacCumber, MD, PhD</b>	8:27 AM	8:30 AM

A Phase 2 Clinical Trial of the Inflammasome Inhibitor K8 in Bilateral Geographic Atrophy (GA)	Jayakrishna Ambati, MD	8:30 AM	8:33 AM
Discussion		8:33 AM	8:45 AM
<i>Transition</i>		8:45 AM	8:47 AM
<b>Closing the Gap: Translating Emerging Therapies into Real-World Outcomes in GA</b>		<b>8:47 AM</b>	<b>9:11 AM</b>
Outcomes in Geographic Atrophy: Real-World Evidence from EHR Data and AI-Based Imaging in Patients Treated with Pegcetacoplan	Nimesh Patel, MD, FASRS	8:47 AM	8:50 AM
Earlier treatment yields better outcomes: 5 years of pegcetacoplan treatment for geographic atrophy secondary to AMD	Esther Kim, MD	8:50 AM	8:53 AM
Real-World Utilization, Retention, Safety, and Outcomes of Pegcetacoplan Therapy for Geographic Atrophy in Patients with Follow-up of Two Years	Alexander Miller, MD	8:53 AM	8:56 AM
Assessment of Geographic Atrophy Progression Following Pegcetacoplan in the Real-world With and Without Neovascular Age-related Macular Degeneration	Hasenin Al-khersan, MD	8:56 AM	8:59 AM
Discussion		8:59 AM	9:11 AM
<i>Transition</i>		9:11 AM	9:13 AM
<b>Inflammatory and Infectious Diseases Symposium. Uveitis and Ocular Infection: Evolving Diagnosis and Treatment Strategies</b>		<b>9:13 AM</b>	<b>9:54 AM</b>
Safety of Anti-VEGF Injections in Patients with Uveitis	Mitchell Allphin, MD	9:13 AM	9:16 AM
Long term visual, anatomical and treatment outcomes in eyes	Sruthi Arepalli, MD	9:16 AM	9:19 AM
Ocular Syphilis and Regional Variation in Lumbar Puncture	Mark Breazzano, MD, FACS	9:19 AM	9:22 AM
Discussion		9:22 AM	9:32 AM
Disease-Modifying Strategies in Autoimmune Retinopathy	Majda Hadziahmetovic, MD	9:32 AM	9:35 AM
Long-Term Outcomes of Pediatric Vogt–Koyanagi–Harada Disease	Sulaiman Al Sulaiman, MD	9:35 AM	9:38 AM
Postoperative Sarocladium kiliense endophthalmitis	Makoto Inoue, MD, FASRS	9:38 AM	9:41 AM
Multimodal Suprachoroidal Space Imaging Reveals Opening	Glenn Yiu, MD, PhD	9:41 AM	9:44 AM
Discussion		9:44 AM	9:54 AM
<i>Transition</i>		9:54 AM	9:56 AM

<b>Trauma &amp; PVR Symposium. <i>Decision-Making, Surgical Strategies, and Case-Based Insights</i></b>		<b>9:56 AM</b>	<b>10:05 AM</b>
Objective Ocular Trauma Score (oOTS): A Visual Acuity-Independent Model With Discrimination Comparable to OTS	<b>Shulamit Schwartz, MD</b>	9:56 AM	9:59 AM
tPA-Assistant Trauma Surgery	<b>Adiel Barak, MD</b>	9:59 AM	10:02 AM
Outcomes of Complex PVR Retinal Detachment Repair with and without Intravitreal Methotrexate at a Single Tertiary Care Center	<b>John Miller, MD</b>	10:02 AM	10:05 AM
Break		<b>10:05 AM</b>	<b>10:45 AM</b>
<b>Hereditary Retinal Disease &amp; Genetics Symposium. <i>Emerging Therapeutic and Diagnostic Advances in Inherited Retinal Diseases</i></b>		<b>10:45 AM</b>	<b>11:06 AM</b>
Intravitreal RNA Therapy for PRPF31-Associated Retinitis Pigmentosa: Results from a Phase 1b Multiple Ascending Dose Study of VP-001	<b>Robert Bhisitkul, MD, PhD</b>	10:45 AM	10:48 AM
Subretinal laru-zova Gene Therapy for XLRP: Preliminary Safety, Efficacy and Surgical Technique in the Phase 2 Multicenter DAWN Trial	<b>Robert Sisk, MD, FACS, FASRS</b>	10:48 AM	10:51 AM
Enhancing Molecular Diagnostic Accuracy in Inherited Retinal Dystrophies Through a Personalized Re-Evaluation Strategy	<b>João Pedro Marques, MD, MSc, PhD, FEBOphth</b>	10:51 AM	10:54 AM
Discussion		10:54 AM	11:06 AM
Transition		11:06 AM	11:08 AM
<b>Diabetic Retinopathy Symposium. <i>Innovations in Diabetic Retinopathy: New Therapies, Delivery Systems, and Disease Biology</i></b>		<b>11:08 AM</b>	<b>11:38 AM</b>
Oral Tonabersat Connexin-43 Modulator for Diabetic Macular Edema with Good Vision (DRCR Protocol AN)	<b>Andrew Barkmeier, MD</b>	11:08 AM	11:11 AM
Sustained-release PER-001 Intravitreal Implant: Structural and Visual Function Improvements in Patients with Diabetic Retinopathy	<b>Saradha Chexal, MD</b>	11:11 AM	11:14 AM
Suprachoroidal Delivery of Investigational Gene Therapy Surabgene Lomparvovec (Sura-vec, ABBV-RGX-314): Results in NPDR at 2.5 Years	<b>David Boyer, MD</b>	11:14 AM	11:17 AM

Adrenaline vs Tranexamic Acid for Intraoperative Hemostasis in PDR Vitrectomy: A Randomized Trial	<b>SHISHIR VERGHESE, MS, FVRS, FAICO (Retina)</b>	11:17 AM	11:20 AM
<b>Fellows Forum Award Winner:</b> Multiomic analysis of human diabetic retinal disease reveals severity and region-specific impairment of the retinal neurovascular unit	<b>Rachana Haliyur, MD, PhD</b>	11:20 AM	11:23 AM
Discussion		11:23 AM	11:38 AM
<i>Transition</i>		11:38 AM	11:40 AM
<b>Retinal Vascular Disease Symposium. <i>Retinal Vascular Occlusions: Treatment Strategies, Outcomes, and Emerging Approaches</i></b>		<b>11:40 AM</b>	<b>12:18 PM</b>
Tiespectus (MK-8748) for the Treatment of Macular Edema Secondary to Branch Retinal Vein Occlusion: Phase 1/2a Rioja Clinical Study	<b>Baruch Kuppermann, MD, PhD, FASRS</b>	11:40 AM	11:43 AM
Retinal Vein Occlusion with Good Baseline Visual Acuity: Immediate Treatment vs. Initial Observation	<b>Ajay Kuriyan, MD, MS</b>	11:43 AM	11:46 AM
Impact of Baseline Central Retinal Thickness on Visual and Anatomic Outcomes in Macular Edema Following RVO: A QUASAR Post hoc analysis through Wk 36	<b>Ehsan Rahimy, MD</b>	11:46 AM	11:49 AM
Discussion		11:49 AM	11:59 AM
Outcomes after low-IOP vitrectomy combined with arteriovenous sheathotomy, ILM peeling with a brief induced IOP fluctuation in Central Retinal Artery Occlusion	<b>Subhendu Boral, MBBS, MD(AIIMS), DNB, FASRS (USA)</b>	11:59 AM	12:02 PM
Clinical Outcomes of Switching Back to Intravitreal Bevacizumab Therapy	<b>Mary Gao, DO</b>	12:02 PM	12:05 PM
Detecting retrobulbar emboli with orbital ultrasonography to predict neovascular glaucoma in central retinal artery occlusion	<b>Erik Massenzio, MD</b>	12:05 PM	12:08 PM
Discussion		12:08 PM	12:18 PM
General Lunch + Fellowship Directors Section Lunch		<b>12:18 PM</b>	<b>1:33 PM</b>
<b>Socioeconomics/Practice Management Panel. <i>Health Systems and Equity in Retina Care</i></b>		<b>1:33 PM</b>	<b>2:03 PM</b>
Impact of Social Deprivation and Vulnerability on Patients With DME: Results From ELEVATUM and YOSEMITE/RHINE	<b>Mohsin Ali, MD</b>		
Baseline Biomarker Levels in Underrepresented Patients With DME: A Post Hoc Exploratory Analysis of ELEVATUM	<b>Adrienne Scott, MD, FASRS</b>		

Real-World Impact of Step Therapy Requirements on Access to Faricimab and Treatment Burden	<b>Sabin Dang, MD</b>		
Impact of Loss of Good Days Copay Assistance Program on Clinical and Anatomical Outcomes of Retinal Disease	<b>Danny Mammo, MD</b>		
Impact of Good Days Underfunding on Treatment Patterns and Outcomes in Patients with Neovascular Age-Related Macular Degeneration	<b>Abdullah Abou-Samra, MD</b>		
Discussion			
<i>Transition</i>		2:03 PM	2:05 PM
<b>Policy Panel</b>		<b>2:05 PM</b>	<b>2:30 PM</b>
<i>Transition</i>		2:30 PM	2:32 PM
<b>Socioeconomics/Practice Management Symposium. Health Disparities in Retina Care: Policy, Geography, and Population Outcomes</b>		<b>2:32 PM</b>	<b>3:10 PM</b>
Access to Intravitreal Anti-VEGF Drugs in Persons with Medicare Advantage Compared with Medicare Fee for Service	<b>Ravi Parikh, MD MPH</b>	2:32 PM	2:35 PM
Comparison of Medicaid vs Medicare Reimbursements Rates for Vitreoretinal Surgeries in the United States	<b>Ella Leung, MD</b>	2:35 PM	2:38 PM
Diabetic Retinopathy Outcomes Among Unhoused Individuals: A Big Data Analysis	<b>Judy Kim, MD, FARVO, FASRS</b>	2:38 PM	2:41 PM
Discussion		2:41 PM	2:51 PM
Impact of Geographic and Socioeconomic Factors on Endophthalmitis Presentation and Outcomes	<b>Bivek Wagle, MD</b>	2:51 PM	2:54 PM
Access to Pediatric Retina Care by Geographic Distribution and US Population Demographic Characteristics in 2025	<b>Hong-Uyen Hua, MD</b>	2:54 PM	2:57 PM
The effects of Social and Demographic Factors on Severity of Inherited Retinal Diseases at the Time of Genetic Testing	<b>Milam Brantley, MD, PhD</b>	2:57 PM	3:00 PM
Discussion		3:00 PM	3:10 PM
<i>Transition</i>		3:10 PM	3:12 PM
Panel Discussion: Impact of Vitrectomy on Light Adjustable Lenses Before Final Laser Lock-in in Post-Cataract Surgery Patients	<b>Osama Sabbagh, MD</b>	3:12 PM	3:27 PM
Break		<b>3:27 PM</b>	<b>4:07 PM</b>

<b>Pediatric Retina - The Michael Trese Symposium in Pediatric Retina</b>		<b>4:07 PM</b>	<b>4:50 PM</b>
ICROP3 Zone I Definition Varies with Post Menstrual Age and is Not Consistent with Type 1 ETROP Treatment Zone I Definition	<b>Darius Moshfeghi, MD, FASRS</b>	4:07 PM	4:10 PM
Tele-screening is associated with reduced treatment rates in a large cohort of infants at risk for retinopathy of prematurity.	<b>Eugenia Greig, MD</b>	4:10 PM	4:13 PM
Retinopathy of Prematurity in Infants Born at 22 Weeks of Gestational Age	<b>Sahal Saleh, MD</b>	4:13 PM	4:16 PM
Discussion		4:16 PM	4:26 PM
Atypical regression patterns of Retinopathy of Prematurity, post combined therapy with intravitreal Anti-VEGF and laser photocoagulation.	<b>Bibhuti Kashyap, MD, FACS, DNB, FRCSEd, FRCS (GLASGOW), FICO</b>	4:26 PM	4:29 PM
Outcomes of a combined surgical approach for stage 5 ROP: A prospective interventional case series	<b>Sameera Nayak, MBBS, MS, FRCS</b>	4:29 PM	4:32 PM
Choroidal Vascularity Index and Choroidal Area in Stage 3+ ROP Eyes Treated With Anti-VEGF With or Without Laser	<b>Swati Agarwal-Sinha, MD, FASRS</b>	4:32 PM	4:35 PM
Comparative Axial Elongation Rates in High Myopia With and Without Retinopathy of Prematurity	<b>Melissa Yuan, MD</b>	4:35 PM	4:38 PM
Discussion		4:38 PM	4:50 PM
<i>Transition</i>		4:50 PM	4:52 PM
<b>MacTel Panel. Macular Telangiectasia Type 2: Imaging, Emerging Therapies, and Clinical Outcomes</b>		<b>4:52 PM</b>	<b>5:22 PM</b>
Ellipsoid Zone Area Loss Is an Independent Predictor of Reduced Fixation Stability in Macular Telangiectasia Type 2	<b>Eleonora Lad, MD, PhD</b>		
Longitudinal Multimodal Imaging and Clinical Outcomes in Individuals Who Received Revakinagene Taroretcel-Iwey Encapsulated Cell Therapy for MacTel	<b>Lydia Sauer, MD</b>		
Reading Speed Outcomes in Macular Telangiectasia Type 2: Sham-Control Data From the Phase 3 Revakinagene Taroretcel-Iwey (NT-501) Trials	<b>Dean Elliott, MD</b>		
Surgical-Related Adverse Events With Revakinagene Taroretcel-Iwey in Macular Telangiectasia Type 2: A Root Cause Analysis	<b>W. Clark, MD, FASRS</b>		

Misdiagnosis of Macular Telangiectasia Type 2 in the Era of Neuroprotective Therapy Discussion	<b>Robin Vora, MD</b>		
Transition		5:22 PM	5:30 PM
<b>WinR Case Conference</b>		<b>5:30 PM</b>	<b>7:15 PM</b>
<b>FIT &amp; Resident Reception</b>		<b>6:00 PM</b>	<b>8:00 PM</b>
<b>Saturday, July 18</b>			
<b>Empowerment &amp; Opportunity Mentoring Breakfast</b>		<b>6:00 AM</b>	<b>8:00 AM</b>
<b>Experience Center (Fellows &amp; Residents)</b>		<b>6:30 AM</b>	<b>7:30 AM</b>
<b>Continental Breakfast</b>		<b>7:15 AM</b>	<b>8:15 AM</b>
<b>Retinal Detachment Panel. <i>Retinal Detachment: PVR Prevention, Surgical Outcomes, and Risk Factors</i></b>			
		<b>8:00 AM</b>	<b>8:20 AM</b>
Statin Use and Association with Proliferative Vitreoretinopathy and Reoperation Risk Following Retinal Detachment Surgery	<b>Christina Weng, MD, MBA, FASRS</b>		
Trends in Centralization of Urgent Versus Elective Vitreoretinal Surgery in the Medicare Fee-For-Service Population: 2017-2023	<b>Stephanie Engelhard, MD</b>		
Interim Report #2 of the FIXER - Methotrexate Trial (Prevention of Proliferative Vitreoretinopathy with Intravitreal Methotrexate in Primary Retinal Detachment Repair)	<b>Christopher Riemann, MD</b>		
Discussion			
<i>Transition</i>		8:20 AM	8:22 AM
<b>Retinal Detachment Symposium 1. <i>Retinal Detachment: Risk Stratification, Prophylaxis, and Imaging Insights</i></b>			
		<b>8:22 AM</b>	<b>8:46 AM</b>
Retinopexy prophylaxis of lattice degeneration in fellow eyes after rhegmatogenous detachment: results from a large national database	<b>Ahmed Shakarchi, MD, MPH</b>		
		8:22 AM	8:25 AM

Retinopexy Prophylaxis for Lattice Degeneration Without Retinal Breaks: A Large Retrospective Cohort Study	Ahmed Sallam, MD PhD FRCOphth	8:25 AM	8:28 AM
Outer Retinal Corrugations Indicate Retinal Break Status in Rhegmatogenous Retinal Detachment	Jeffrey Mah, MD	8:28 AM	8:31 AM
Outer Retinal Corrugation Biomechanics Predict Outer Retinal Folds and Visual Acuity in Rhegmatogenous Retinal Detachment	Isabela Martins Melo, MD	8:31 AM	8:34 AM
Discussion		8:34 AM	8:46 AM
<i>Transition</i>		8:46 AM	8:48 AM
<b>Hereditary Retinal Disease &amp; Genetics Panel. <i>Stargardt Disease: Emerging Therapies, Biomarkers, and Clinical Trial Design</i></b>		<b>8:48 AM</b>	<b>9:13 AM</b>
Results of the Phase 3 DRAGON Trial of Tinlarebant (LBS-008) for Stargardt Disease (STGD1)	Paul Bernstein, MD, PhD		
Oral Gildeuretinol for Slowing Stargardt Disease Progression: Safety and Efficacy Data from the Phase 2 TEASE Study and Follow-up Phase 3 Study Design	Christine Kay, MD		
Relationship of Three Atrophy Growth Rate Metrics with Lesion Shape Factors in Stargardt Disease: Implications for Clinical Trial Design	Liangbo Shen, MD		
Automated Quantification of Decreased FAF in Stargardt Disease Using Starguage: Validation Against Manual Grading Standards	Jia-Horung Hung, MD, PhD		
Discussion			
<i>Transition</i>		9:13 AM	9:15 AM
<b>Best of JVRD and Journal Updates</b>	<b>Moderator: Timothy Murray, MD, MBA, FASRS</b>	<b>9:15 AM</b>	<b>9:30 AM</b>
<i>Transition</i>		9:30 AM	9:32 AM
Break		<b>9:32 AM</b>	<b>10:12 AM</b>
<b>Pharmacology Symposium. <i>Balancing Risk and Benefit: Pharmacologic Safety in Retina Care</i></b>		<b>10:12 AM</b>	<b>10:36 AM</b>
Association of Peri-Event Anti-VEGF with Mortality and Sequelae Following Stroke or Myocardial Infarction	Darius Bordbar, MD	10:12 AM	10:15 AM

Safety of Continuing Anti-VEGF Therapy Around the Time of Nonophthalmic Incisional Surgery: A Multisite Matched Cohort Study	<b>Odette Houghton, MD</b>	10:15 AM	10:18 AM
'Drop less Vitrectomy' with 'Suprachoroidal Trimoxi' for epiretinal membranes: A Comparative Analysis of Safety and Efficacy with standard of care topi	<b>K. Chalam, MD, PhD, MBA, FRCS(C), FASRS</b>	10:18 AM	10:21 AM
A Pilot Study Evaluating Safety and Patient Comfort of a Compounded Povidone-Iodine and Proparacaine Combination	<b>Ivan Suñer, MD, MBA</b>	10:21 AM	10:24 AM
Discussion		10:24 AM	10:36 AM
<i>Transition</i>		10:36 AM	10:38 AM
<b>AMD - Non-neovascular Symposium 3. Geographic Atrophy: Functional Outcomes, Treatment Response, and Predictive Biomarkers</b>		<b>10:38 AM</b>	<b>10:57 AM</b>
Structure–Function Link of the Ellipsoid Zone and Low Luminance Deficit in Geographic Atrophy with Monthly and Every-Other-Month Avacincaptad Pegol	<b>Rachel Downes, MD</b>	10:38 AM	10:41 AM
Pegcetacoplan versus Avacincaptad pegol: Efficacy of Treatment in the Same Eye	<b>Josh Wallsh</b>	10:41 AM	10:44 AM
Baseline Characteristics Associated With Loss of BCVA $\geq$ 15 ETDRS Letters in Participants With Geographic Atrophy in the Phase 2 ARCHER Study	<b>Margaret Chang, MD, MS</b>	10:44 AM	10:47 AM
Discussion		10:47 AM	10:57 AM
<i>Transition</i>		10:57 AM	10:59 AM
<b>Real-World Retina: Outcomes, Complications, and Risk Stratification</b>		<b>10:59 AM</b>	<b>11:30 AM</b>
Incidence, prevalence and risk factors for pathologic myopia and associated complications: a multi-center database study	<b>Michael Flitsos, MD</b>	10:59 AM	11:02 AM
Incidence and risk factors of retinal tear and detachment after YAG capsulotomy: an IRIS® Registry (Intelligent Research in Sight) analysis	<b>Jordan Deaner, MD</b>	11:02 AM	11:05 AM
Ten-Year Real-World Outcomes of Intravitreal Antibiotics Alone, Deferred Vitrectomy, and Immediate Vitrectomy for Acute Post-Cataract Endophthalmitis	<b>Aditya Kelkar, MS, FRCS, FASRS, FRCOphth</b>	11:05 AM	11:08 AM

Discussion		11:08 AM	11:18 AM
Endophthalmitis Following Pars Plana Vitrectomy: An IRIS® Registry Study	<b>Matthew Starr, MD, FASRS</b>	11:18 AM	11:21 AM
Proliferative Vitreoretinopathy in Contemporary Retinal Detachment Surgery: Socioeconomic, Surgical, and Ocular Determinants in the IRIS® Registry	<b>Leo Kim, MD, PhD</b>	11:21 AM	11:24 AM
Discussion		11:24 AM	11:30 AM
<i>Transition</i>		11:30 AM	11:32 AM
<b>Macular Holes &amp; Macular Pucker Panel 2. Macular Surgery Complications: Outcomes After Vitrectomy for Hole and Pucker</b>		<b>11:32 AM</b>	<b>11:57 AM</b>
Persistent cystoid macular edema after vitrectomy for epiretinal membrane removal	<b>Libby Wei, MD</b>		
Epiretinal Membrane Risk After Prophylactic Laser Photocoagulation for Lattice Degeneration	<b>Marta Stevanovic, MD, MSc</b>		
Increased Risk of Retinal Detachment in Combined Phacovitrectomy versus Sequential Surgery for Macular	<b>Charles Zhang, MD</b>		
Progression of Macular Atrophy after Vitrectomy for Myopic Traction Maculopathy: Incidence, Risk Factors, and Outcomes	<b>Taku Wakabayashi, MD, PhD</b>		
Discussion			
General Lunch + WinR Lunch		<b>11:57 AM</b>	<b>1:12 PM</b>
<b>Retinaws</b>	<b>Moderator: Kourous Rezaei, MD</b>	<b>1:12 PM</b>	<b>2:12 PM</b>
	Panelists: Audina Berrocal, MD, FASRS; Maria Berrocal, MD; Geoffrey G. Emerson, MD, PhD, FASRS; Gustavo Hüning, MD, MBA, FASRS; Makoto Inoue, MD, FASRS; Kazuaki Kadonosono, MD; Stanislao Rizzo, MD; Gaurav Shah, MD; Christina Weng, MD, MBA, FASRS; Charles Wykoff, MD, PhD, FASRS		
<i>Transition</i>		2:12 PM	2:14 PM
<b>Ocular Oncology Symposium. Uveal Melanoma: From Biopsy to Biomarkers to Clinical Decision-Making</b>		<b>2:14 PM</b>	<b>2:44 PM</b>

Viscous Fluid Control Assisted Fine-Needle Aspiration Biopsy for Uveal Melanoma: Surgical Technique	<b>Gordon Crabtree, MD</b>	2:14 PM	2:17 PM
Gene Expression Profiling for Uveal Melanoma: The first decade and beyond defines best care for our patients	<b>Timothy Murray, MD, MBA, FASRS</b>	2:17 PM	2:20 PM
Limits of Mutation Profiling as a Predictor of 15-GEP/PRAME Risk in Uveal Melanoma	<b>David Reichstein, MD</b>	2:20 PM	2:23 PM
Clinicopathologic characteristics, gene expression, and metastatic risk of uveal melanomas with no uveal melanoma-associated mutations (no UMAMs)	<b>Amy Scheffler, MD FACS FASRS</b>	2:23 PM	2:26 PM
Prophylactic bevacizumab after Plaque Brachytherapy in high-risk posterior uveal melanoma: Impact on development of radiation retinopathy	<b>Prithvi Mruthyunjaya, MD, MHS</b>	2:26 PM	2:29 PM
Discussion		2:29 PM	2:44 PM
Break		<b>2:44 PM</b>	<b>3:24 PM</b>
<b>Best of Business of Retina</b>	<b>Moderator: Thomas Stone, MD</b>	3:24 PM	3:39 PM
<i>Transition</i>		3:39 PM	3:41 PM
<b>Creative Awards</b>		<b>3:41 PM</b>	<b>4:06 PM</b>
<i>Transition</i>		4:06 PM	4:08 PM
<b>Diabetic Retinopathy Panel 2. <i>Diabetic Retinopathy: Outcomes and Predictors</i></b>		<b>4:08 PM</b>	<b>4:33 PM</b>
Impact of Baseline Subretinal Fluid on Treatment Outcomes in DME: Analysis of the Phase 3 YOSEMITE and RHINE Trials	<b>Rolake Alabi, MD PhD</b>		
Baseline Macular Vascular Status Determines Perfusion and Visual Recovery After Panretinal Photocoagulation in Severe Diabetic Retinopathy Without Macular Edema	<b>Eoi Jong Seo, MD, PhD</b>		
Assessment of Intraretinal Cyst Turbidity on Optical Coherence Tomography: Clinical Implications in DME From YOSEMITE/RHINE	<b>Andreas Pollreisz, MD</b>		
The Association Between Diabetic Retinopathy Severity and Dementia Risk	<b>Manju Subramanian, MD</b>		
Discussion			
<i>Transition</i>		4:33 PM	4:35 PM

<b>Retinal Detachment Symposium 2. <i>Beyond Routine RD: Complex Cases, AI Prediction, and Surgical Decision-Making</i></b>		<b>4:35 PM</b>	<b>4:59 PM</b>
Predicting the Location of Retinal Tears in Eyes with Rhegmatogenous Retinal Detachment Using Artificial Intelligence	<b>John Thompson, MD</b>	4:35 PM	4:38 PM
Clinical features of retinal detachment (RD) following prophylactic retinopexy in children with Stickler syndrome: implications for optimal treatment and management	<b>Franco Recchia, MD</b>	4:38 PM	4:41 PM
Colobomatous Retinal Detachments: A Single Center Retrospective Analysis	<b>Amer Alsoudi, MD</b>	4:41 PM	4:44 PM
Scleral Buckle Revision in the Vitrectomy Era	<b>Irmak Karaca, MD, FEBO, FICO, MRCSEd</b>	4:44 PM	4:47 PM
Discussion		4:47 PM	4:59 PM
Closing Reception: Marche Bonsecours		7:00 PM	